FDA Ad Comm Recommends New Mylotarg Dose for AML

Clinical Trials Advisor
A A
An FDA advisory committee voted to recommend that Wyeth’s Mylotarg return to the U.S. market as a treatment for CD33-positive acute myeloid leukemia in combination with daunorubicin and cytarabine.

To View This Article:

Login

Subscribe To Clinical Trials Advisor